SK pharmteco’s Three-Business-Unit Strategy: Small Molecules, Peptides, and Viral Vectors

SK pharmteco is doubling down on its growth by injecting $100 million into its cell and gene therapy division to complement its established strengths in small molecules and peptides. CEO Joerg Ahlgrimm stresses that the company’s competitive edge lies not just in its global manufacturing footprint across the US, Europe, and Asia, but in a decentralized culture that empowers frontline employees to connect their daily work directly to patient outcomes. Looking toward the next decade, the discussion explores how the integration of AI and a shift toward regionalized supply chains will redefine the CDMO landscape, positioning the firm as a multi-modal leader in an increasingly complex market.